Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 265

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Targeting interleukin‐15 in patients with rheumatoid arthritis: A proof‐of‐concept study

Baslund, Bo, Tvede, Niels, Danneskiold‐Samsoe, Bente, Larsson, Per, Panayi, Gabriel, Petersen, Joergen, Petersen, Lars J., Beurskens, Frank J. M., Schuurman, Janine, van de Winkel, Jan G. J., Parren, Paul W. H. I., Gracie, J. Alastair, Jongbloed, Sarah, Liew, Foo Y., McInnes, Iain B. · 2005 · Arthritis & Rheumatism

Abstract

Objective: Interleukin‐15 (IL‐15) is a proinflammatory, innate response cytokine that mediates pleiotropic effector function in rheumatoid arthritis (RA) inflammatory synovitis. Our objective was to study the ability of HuMax‐IL15, a human IgG1 anti–IL‐15 monoclonal antibody, to neutralize exogenous and endogenous IL‐15 activity in vitro and to perform a phase I–II dose‐escalation trial with HuMax‐IL15 in patients with active RA. Methods: Mononuclear cells from blood and synovial fluid (SF) of RA patients were isolated and cultured in vitro under experimental conditions involving the addition of HuMax‐IL15. HuMax‐IL15 was administered to 30 RA patients who received no other disease‐modifying antirheumatic drugs in a 12‐week, dose‐ascending, placebo‐controlled, double‐blind, phase I–II proof‐of‐concept study. Results: In vitro studies showed that HuMax‐IL15 suppressed proliferation and induced apoptosis in an IL‐15–dependent cell line, BDB2, and was capable of suppressing the release of interferon‐γ by synovial fluid mononuclear cell (SFMC) cultures induced by exogenous IL‐15. Furthermore, HuMax‐IL15 F(ab′)2 fragments suppressed exogenous IL‐15–induced CD69 expression in RA peripheral blood mononuclear cells and SFMCs, which indicates that HuMax‐IL15 can specifically neutralize several biologic effects of IL‐15 in synovial tissue in vitro. In a phase I–II clinical trial, HuMax‐IL15 was well tolerated clinically, with no significant effects on T lymphocyte subset and natural killer cell numbers. Substantial improvements in disease activity were observed according to the American College of Rheumatology criteria for 20% improvement (63% of patients), 50% improvement (38%), and 70% improvement (25%). Conclusion: These clinical data suggest for the first time that IL‐15 could represent a novel therapeutic target in RA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.21249

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 265

Metadata

Authors
Baslund, B., Tvede, N., Danneskiold‐Samsoe, B., Larsson, P., Panayi, G., Petersen, J., Petersen, L. J., Beurskens, F. J. M., Schuurman, J., van de Winkel, J. G. J., Parren, P. W. H. I., Gracie, J. A., Jongbloed, S., Liew, F. Y., & McInnes, I. B.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2005-09
Volume
52
Issue
9
Pages
2686-2692
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W1999709426
Cited by
265
References
32
FWCI
13.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting interleukin‐15 in patients with rheumatoid arthritis: A proof‐of‐concept study. https://app.cochat.ai/papers/10.1002/art.21249
The paper
Baslund, B., Tvede, N., Danneskiold‐Samsoe, B., Larsson, P., Panayi, G., Petersen, J., Petersen, L. J., Beurskens, F. J. M., Schuurman, J., van de Winkel, J. G. J., Parren, P. W. H. I., Gracie, J. A., Jongbloed, S., Liew, F. Y., & McInnes, I. B. (2005). Targeting interleukin‐15 in patients with rheumatoid arthritis: A proof‐of‐concept study. Arthritis & Rheumatism. https://doi.org/10.1002/art.21249

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.